AbbVie Inc. shares slid 2.3% in premarket trade Friday, after the drug company posted weaker-than-expected profit and revenue for the fourth quarter. AbbVie said it had a net loss of $1.826 billion, or $1.23 a share, in the quarter, after earnings of $52 million, or 3 cents a share, in the year-earlier period. The loss was due to an impairment charge related to intangible assets acquired as part of the 2016 acquisition of Stemcentrx Inx. Adjusted per-share earnings came to $1.90, below the FactSet consensus of $1.94. Revenue rose to $8.305 billion from $7.739 billion, also below the FactSet consensus of $8.350 billion. Sales of the company’s key Humira treatment for arthritis, plaque psoriasis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis rose 0.5% and were up 9.1% in the U.S. The company said it now expects 2019 EPS of $7.39 to $7.49, or adjusted EPS of $8.65 to $8.75. The current FactSet consensus is $8.72. Shares have fallen 20.7% in the last 12 months, while the S&P 500 has fallen 6.9%.